Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | GRM5 | P41594 | 4/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513177 | 0.84 | HDAC4 (0.53) | GBA1GPR119GRM5HDAC4MAPT | |
| SCHEMBL512846 | 0.82 | KDM4E (0.46) | GBA1PKMGPR119GRM5HDAC4 | |
| SCHEMBL513424 | 0.81 | LMNA (0.45) | GBA1LMNAGPR119GRM5TSHR | |
| SCHEMBL513325 | 0.79 | KCNH2 (0.49) | GRM5HDAC4 | |
| SCHEMBL512506 | 0.78 | GBA1 (0.46) | GBA1LMNAPKMGPR119GRM5 | |
| SCHEMBL4415549 | 0.78 | LMNA (0.64) | LMNAPKMGRM5TSHRHTT | |
| SCHEMBL513293 | 0.78 | GRM5 (0.46) | GPR119GRM5HDAC4 | |
| SCHEMBL12580644 | 0.77 | LMNA (0.78) | GBA1LMNAPKMGPR119HTT | |
| SCHEMBL514361 | 0.75 | GRM5 (0.41) | GPR119GRM5HDAC4HTTRAB9A | |
| SCHEMBL4139808 | 0.74 | GRM5 (0.69) | LMNAPKMGRM5TSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | GBA1 1218/4885LMNA 1601/4885PKM 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.